Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK

• Published in: Nature medicine Vol. 27; no. 12; pp. 2127 - 2135
• Main Authors: Pouwels, Koen B., Pritchard, Emma, Matthews, Philippa C., Stoesser, Nicole, Eyre, David W., Vihta, Karina-Doris, House, Thomas, Hay, Jodie, Bell, John I., Newton, John N., Farrar, Jeremy, Crook, Derrick, Cook, Duncan, Rourke, Emma, Studley, Ruth, Peto, Tim E. A., Diamond, Ian, Walker, A. Sarah
• Format: Journal Article
• Language: English
• Published: New York Nature Publishing Group US 01.12.2021; Nature Publishing Group
• Subjects: 692/699/255/2514; 692/700/478/174; Adolescent; Adult; Antibodies, Neutralizing - blood; Antibodies, Viral - blood; Attenuation; Biomedical and Life Sciences; Biomedicine; BNT162 Vaccine - immunology; Cancer Research; ChAdOx1 nCoV-19 - immunology; Coronaviruses; COVID-19; COVID-19 - epidemiology; COVID-19 - immunology; COVID-19 - prevention & control; Households; Humans; Infection control; Infections; Infectious Diseases; Measurement; Metabolic Diseases; Methods; Middle Aged; Molecular Medicine; Neurosciences; Polymerase Chain Reaction; Respiratory diseases; SARS-CoV-2 - immunology; Severe acute respiratory syndrome coronavirus 2; United Kingdom - epidemiology; Vaccination; Vaccine efficacy; Vaccine Efficacy - statistics & numerical data; Vaccines; Viral diseases; Viral Load; Viremia; Young Adult; United Kingdom; United Kingdom > UK
• ISSN: 1078-8956; 1546-170X; 1546-170X
• DOI: 10.1038/s41591-021-01548-7

The effectiveness of the BNT162b2 and ChAdOx1 vaccines against new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections requires continuous re-evaluation, given the increasingly dominant B.1.617.2 (Delta) variant. In this study, we investigated the effectiveness of these vaccines...